SCHEMBL3309738

SCHEMBL3309738

CN1CCCC[C@H]1C[C@H](O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.72
CYP1A2 P05177 3/20 0.72
HIF1A Q16665 1/20 0.72
SLC18A2 Q05940 3/20 0.56
LMNA P02545 2/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
CHRNB2 P17787 1/20 0.56
HTR2A P28223 1/20 0.56
HRH1 P35367 1/20 0.56
CHRNA7 P36544 1/20 0.56
CHRNA4 P43681 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30136172 1.00 CYP2D6 (0.72) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL23415178 1.00 CYP2D6 (0.72) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL11447464 0.95 CYP2D6 (0.74) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL21483299 0.86 CYP1A2 (0.51) CYP2D6CYP1A2HIF1ACHRNB2CHRNA7
SCHEMBL5948954 0.85 CYP2D6 (0.52) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL5949491 0.85 CYP2D6 (0.52) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL5948941 0.85 CYP2D6 (0.52) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL5949017 0.85 CYP2D6 (0.52) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL5949021 0.85 CYP2D6 (0.52) CYP2D6CYP1A2HIF1ASLC18A2LMNA
SCHEMBL5948950 0.85 CYP2D6 (0.52) CYP2D6CYP1A2HIF1ASLC18A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370177-B1 NOVEL COSMETIC COMPOSITIONS HAVING HAIR GROWTH INHIBITING EFFECT HENKEL AG & CO KGAA (DE) 2017-11-15 EP claimed
EP-4731602-A1 NEW CLASS OF LIPIDS FOR DELIVERING ACTIVE INGREDIENTS INTO CELLS OZ Biosciences (FR) 2026-04-29 EP disclosed
US-12539298-B2 Lobinaline N-oxides as positive allosteric modulators of the dopamine transporter with potential value in the treatment of substance abuse disorders UNIV KENTUCKY RES FOUND (US) 2026-02-03 US disclosed
WO-2025080590-A1 CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS SCIENTIFIC HORIZONS CONSULTING LLC (US) 2025-04-17 WO disclosed
CN-113811532-B Pesticidally active heterocyclic derivatives with sulfur containing substituents 先正达农作物保护股份公司 2025-04-11 CN disclosed
WO-2024261311-A1 NEW CLASS OF LIPIDS FOR DELIVERING ACTIVE INGREDIENTS INTO CELLS OZ BIOSCIENCES (FR) 2024-12-26 WO disclosed
EP-4480943-A1 NEW CLASS OF LIPIDS FOR DELIVERING ACTIVE INGREDIENTS INTO CELLS Oz Biosciences (FR) 2024-12-25 EP disclosed
CN-112839933-B Pesticidally active benzene-amide and azine-amide compounds 先正达参股股份有限公司 2024-12-13 CN disclosed
WO-2024189588-A1 BEVERAGES CONTAINING NATURAL PRODUCTS KENNEDY J PHILLIP (US) 2024-09-19 WO disclosed
US-20240307472-A1 BEVERAGES CONTAINING NATURAL PRODUCTS PK Beverages LLC (US) 2024-09-19 US disclosed
US-20170107208-A1 SYNTHETIC PROCESS THE UNIVERSITY OF LIVERPOOL (GB) 2017-04-20 US disclosed
EP-3122725-A1 SYNTHETIC PROCESS The University of Liverpool (GB) 2017-02-01 EP disclosed
WO-2015145143-A1 SYNTHETIC PROCESS THE UNIVERSITY OF LIVERPOOL (GB) 2015-10-01 WO disclosed
CN-104840505-A Application of aizoon stonecrop herb to preparation of composition for inhibiting itching caused by mosquito bite LUOYANG GUCHENG BIOTECHNOLOGY CO LTD 2015-08-19 CN disclosed
US-20100098788-A1 Extracts of Curcuma and Methods of Use Thereof HERBALSCIENCE GROUP, LLC 2010-04-22 US disclosed
EP-1360327-A4 METHOD FOR IDENTIFYING GENES REGULATING DESIRED CELL PHENOTYPES GALILEO PHARMACEUTICALS INC (US) 2005-07-13 EP disclosed
EP-1360327-A1 METHOD FOR IDENTIFYING GENES REGULATING DESIRED CELL PHENOTYPES PHYTERA, INC. (US) 2003-11-12 EP disclosed
WO-2002059374-A1 METHOD FOR IDENTIFYING GENES REGULATING DESIRED CELL PHENOTYPES PHYTERA, INC. (US) 2002-08-01 WO disclosed
US-6362009-B1 CAPTURING A SUBSTRATE ON SOLID SUPPORT AND ACTIVATINGSUBSTRATE TO REACT WITH REAGENT WITH WHICH UNACTIVATED SUBSTRATE DOES NOT REACT; REACTING ACTIVATED SUBSTRATE ON SOLID PHASE WITH REAGENT TO GIVE AN ADDITION PRODUCT MERCK & CO., INC. 2002-03-26 US disclosed
US-4556515-A CONDENSATION OF AN OXIME SULFATE AND SILYL ENOL ETHER TOYO STAUFFER CHEMICAL CO., LTD. (JP) 1985-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12539298-B2 Lobinaline N-oxides as positive allosteric modulators of the dopamine transporter with potential value in the treatment of substance abuse disorders SLC18A3, SLC18A2, SLC6A3 CYP2D6 1327/4885CYP1A2 654/4885HIF1A 4654/4885
US-20240307472-A1 BEVERAGES CONTAINING NATURAL PRODUCTS FABP3, SIRT3, SIRT5 CYP2D6 2642/4885CYP1A2 3155/4885HIF1A 949/4885
US-20170107208-A1 SYNTHETIC PROCESS PIR, SRM, SMS CYP2D6 111/4885CYP1A2 176/4885HIF1A 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.